clinical trial · NCT07518043
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Esophageal and/or Cardia CancerMelanomaUrothelial Carcinoma (UC)HLX18OPDIVO®
brief summary
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety and immunogenicity of HLX18 and OPDIVO® in patients with resected esophageal or gastroesophageal junction cancer (EC/GEJC), melanoma (MEL), or urothelial carcinoma (UC).
started
Jul 15, 2026
primary completion
Aug 12, 2027
completion
Jun 13, 2028
last updated
Jul 24, 2026
official title
A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetic Profile, Efficacy, Safety and Immunogenicity of HLX18 vs. OPDIVO® (US-sourced OPDIVO®) in Multiple Resected Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol